The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
NCT: NCT05836987 · RECRUITING
Brief Summary
REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.
Frequently Asked Questions
What is The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation?
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation is a clinical trial registered under NCT05836987. Current status: RECRUITING.
What is the status of NCT05836987?
The current status of NCT05836987 (The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation) is: RECRUITING.
When did The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation start?
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation started on 2023-07-13.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.